Investigation Launched Against Nyxoah S.A. by Pomerantz LLP
New York, April 14, 2025 – Pomerantz LLP, a leading securities law firm, is investigating potential claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). The investigation concerns allegations of securities fraud and other potential violations of federal securities laws.
Background on Nyxoah S.A.
Nyxoah is a Belgian neurostimulation company that focuses on developing and marketing solutions for the treatment of sleep apnea. Its flagship product is the Gentag™ system, a wireless, implantable neurostimulation system that uses a patient’s natural breathing patterns to provide therapy.
Allegations of Securities Fraud
According to the investigation, certain allegations have been raised regarding Nyxoah’s financial statements and business practices. Specifically, it has been suggested that the Company may have misrepresented the commercial success of its Gentag™ system and the progress of its clinical trials.
Impact on Investors
The investigation could have significant implications for Nyxoah’s investors. If it is determined that the Company engaged in securities fraud or other violations of federal securities laws, shareholders may be entitled to recover their losses through a class action lawsuit. The size and scope of any potential recovery would depend on the specifics of the case and the damages suffered by individual investors.
Impact on the World
Beyond the immediate impact on Nyxoah’s investors, the investigation could have broader implications for the medical device industry and the field of neurostimulation more broadly. If it is found that the Company misrepresented the commercial success or safety of its product, it could undermine public trust in neurostimulation technology and the companies that produce it.
Conclusion
The investigation into Nyxoah S.A. by Pomerantz LLP is an important development for the Company and its investors. The allegations of securities fraud and other potential violations of federal securities laws could have significant consequences for those who have invested in the Company. Meanwhile, the potential implications for the medical device industry and the field of neurostimulation are more far-reaching, and it will be important to monitor the progress of the investigation closely.
- Pomerantz LLP is investigating claims of securities fraud and other violations of federal securities laws against Nyxoah S.A.
- The investigation concerns allegations that the Company misrepresented the commercial success and progress of its Gentag™ system.
- The investigation could have significant implications for Nyxoah’s investors, who may be entitled to recover their losses through a class action lawsuit.
- Beyond the immediate impact on investors, the investigation could also have broader implications for the medical device industry and the field of neurostimulation.
